瑞加诺生与双嘧达莫对比:CZT-SPECT相机上负荷心肌血流反应的评估
该回顾性研究纳入228例动态CZT-SPECT心肌灌注显像患者(瑞加诺生66例、双嘧达莫162例),比较负荷心肌血流量(MBF)与心肌血流储备(MFR)。总体瑞加诺生组负荷MBF较高(1.71 ± 0.73 vs 1.44 ± 0.55 mL·min-1·g-1,p < .05),但排除混杂因素后匹配的41对患者中负荷MBF与MFR均无显著差异,提示两种药物在可比患者中诱导的充血程度相当。
要点
- 总体瑞加诺生组负荷MBF高于双嘧达莫组(1.71 ± 0.73 vs 1.44 ± 0.55 mL·min-1·g-1,p < .05)。
- 匹配排除高心血管风险患者后,两组负荷MBF无显著差异(双嘧达莫1.57 ± 0.56 vs 瑞加诺生1.61 ± 0.62 mL·min-1·g-1,p = .88)。
- 匹配后两组MFR亦无显著差异(双嘧达莫2.62 ± 0.77 vs 瑞加诺生2.46 ± 0.76,p = .40)。
核心结论
- 结果提示在可比患者中,双嘧达莫与瑞加诺生诱导的充血程度相当,动态SPECT测得的负荷MBF与MFR相似。
研究设计与样本
- 回顾性分析228例接受动态CZT-SPECT心肌灌注显像的患者,其中瑞加诺生负荷66例、双嘧达莫负荷162例。
- 为排除混杂因素,亚分析中匹配了两组各41例临床特征可比的患者,并排除高心血管风险患者。
主要发现
- 总体瑞加诺生组负荷MBF高于双嘧达莫组(1.71 ± 0.73 vs 1.44 ± 0.55 mL·min-1·g-1,p < .05)。
- 匹配后负荷MBF在双嘧达莫组为1.57 ± 0.56 mL·min-1·g-1,瑞加诺生组为1.61 ± 0.62 mL·min-1·g-1,两组无显著差异(p = .88)。
- 匹配后MFR在双嘧达莫组为2.62 ± 0.77,瑞加诺生组为2.46 ± 0.76,两组无显著差异(p = .40)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regadenoson is a selective adenosine receptor agonist. It is currently unclear if the level of hyperemia differs between stress agents. We compared Myocardial Blood Flow (MBF) and Myocardial Flow Reserve (MFR) response on CZT-SPECT Myocardial Perfusion Imaging (MPI) to evaluate if dipyridamole and regadenoson could induce the same level of hyperemia. METHODS: 228 patients with dynamic CZT-SPECT MPI were retrospectively analyzed (66 patients stressed with regadenoson and 162 with dipyridamole) in terms of MBF and MFR. To rule out confounding factors, two groups of 41 patients were matched for clinical characteristics in a sub-analysis, excluding high cardiovascular risk patients. RESULTS: Overall stress MBF was higher in regadenoson patients (1.71 ± 0.73 vs. 1.44 ± 0.55 mL·min-1·g-1 for regadenoson and dipyridamole, respectively, p < .05). However, when confounding factors were ruled out, stress MBF (1.57 ± 0.56 vs. 1.61 ± 0.62 mL·min-1·g-1 for dipyridamole and regadenoson, respectively, p = .88) and MFR (2.62 ± 0.77 vs. 2.46 ± 0.76 for dipyridamole and regadenoson, respectively, p = .40) were not different between regadenoson and dipyridamole. CONCLUSIONS: Our results suggest that dipyridamole and regadenoson induce equivalent hyperemia in dynamic SPECT with similar stress MBF and MFR in comparable patients.
引用
- Brana Q, Thibault F, Courtehoux M, et al. Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera. J Nucl Cardiol. 2020. PMID: 32651801. doi:10.1007/s12350-020-02271-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。